About BroadenBio

About BroadenBio

——

Team

图片名称

Core Team

Consultant

Team

Xingmin Zhang MD, Ph.D.

Xingmin Zhang MD, Ph.D.

Founder, Chairman & CEO

BroadenBio’s HPK1 Inhibitor Selected for Poster Presentation in AACR 2023

BB3008, an investigational Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor independently discovered and developed by BroadenBio, has been selected as the "Late-Breaking Research" at the 2023 annual meeting of the American Association for Cancer Research (AACR) recently. The preclinical data of BB3008 will be presented in the poster session on April 19, 2023. The information has been published on the AACR official website.

BroadenBio Announces First Patient Dosed in Phase 1 Study of BB102 in China

BB102 Received FDA Approval for Clinical Trials in Patients with Advanced Solid Tumors

BB102 Approved for Clinical Trials in Patients with Advanced Solid Tumors

BroadenBio Completed PreA+ Round of Financing, Building Immunology and Small Molecule Coupling Technology Platform

< 1 2 3 4 5 6 >

address：

A1-602, 88 Kechuang 6th Street, BDA, Beijing 100176

phone：

e-mail：

hr@broadenbio.com

Copyright ©2019 BroadenBio

Powered by www.300.cn

business license